Polypharmacotherapy in Psychiatry: Global Insights from a Rapid Online Survey of Psychiatrists
Open Access
- 11 April 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (8) , 2129
Abstract
In recent years, an increase in the problem of polypharmacotherapy in psychiatric patients has been observed, including the widespread problem of groups of people taking new psychoactive substances. One reason for this problem may be the poor knowledge of pharmacological interactions in psychiatry. The aim of this study was to explore the opinions and knowledge of psychiatrists from around the world on various aspects related to polypharmacotherapy. A total of 1335 psychiatrists from six continents were included in the study. The respondents’ opinion on the problem of hepatotoxicity in psychiatry was also examined. The greatest discrepancy among psychiatrists from different continents in the answers given concerned the definition of polypharmacotherapy (p < 0.001) and the approach to hepatotoxicity (p < 0.001). It is noteworthy that only about 20% of the psychiatrists surveyed (p < 0.001) believe that polypharmacotherapy is associated with a higher rate of patients’ hospitalisations. The most commonly used type of polypharmacy by psychiatrists was antidepressants and antipsychotics. Most of them also stated that polypharmacy was associated with reduced patient compliance with the doctor’s recommendations related to taking medications due to the increased complexity of the therapy. The continent that diversified the analysed questions to the greatest extent was Africa. Future educational activities for trainee psychiatrists should include more discussion of polypharmacotherapy in psychiatry.Keywords
This publication has 45 references indexed in Scilit:
- Polypharmacy in psychiatry: A reviewMens Sana Monographs, 2013
- Polypharmacy With Common Diseases in Hospitalized Elderly PatientsThe American Journal of Geriatric Pharmacotherapy, 2012
- Which psychotropic medications induce hepatotoxicity?General Hospital Psychiatry, 2011
- Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behaviorSchizophrenia Research, 2011
- Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open‐label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidoneHuman Psychopharmacology: Clinical and Experimental, 2008
- Duplicative medications in patients who visit multiple medical institutions among the insured of a corporate health insurance society in JapanHealth Policy, 2008
- When Less Is More: Reducing the Incidence of Antipsychotic PolypharmacyJournal of Psychiatric Practice, 2007
- Benzodiazepine Use and Abuse Among Patients With Severe Mental Illness and Co-occurring Substance Use DisordersPsychiatric Services, 2003
- The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patientsPsychiatric Bulletin, 2002
- Racial Disparities in Antipsychotic Prescription Patterns for Patients With SchizophreniaAmerican Journal of Psychiatry, 2002